ALK-1/Activin RL1, His, Human
ALK-1/Activin RL1, His, Human

Measured by its ability to inhibit BMP9 induced alkaline phosphatase production by ATDC5 mouse chondrogenic cells. The ED50 for this effect is <50 ng/mL in the presence of 2 ng/mL of recombinant human BMP9 (Cat.GDF-HM002).

ALK-1/Activin RL1, His, Human

Immobilized Human GDF-2, No Tag at 2 μg/ml (100 μI/well) on the plate. Dose response curve for ALK-1/Activin RL1, His, Human, His Tag with the EC50 of 6.6ng/ml determined by ELISA.

ALK-1/Activin RL1, His, Human

The purity of ALK-1/Activin RL1, His, Human is greater than 95% as determined by SEC-HPLC.

ALK-1/Activin RL1, His, Human

ALK-1/Activin RL1, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

ALK-1/Activin RL1, His, Human

Activin receptor-like kinase 1 (ALK1)-mediated endothelial cell signalling in response to bone morphogenetic protein 9 (BMP9) and BMP10 is of significant importance in cardiovascular disease and cancer. Structural analyses reveal a tripartite recognition mechanism that defines BMP9 and BMP10 specificity for ALK1, and predict that crossveinless 2 is not an inhibitor of BMP9, which is confirmed by experimental evidence.
Z05005
¥55,963.00

Ask us a question
Product Introduction
Species Human
Protein Construction
ALK-1/Activin RL1 (Asp22-Gln118)
Accession # P37023		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 11.5 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 25-30 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • ALK-1/Activin RL1, His, Human
    • ALK-1/Activin RL1, His, Human

    Measured by its ability to inhibit BMP9 induced alkaline phosphatase production by ATDC5 mouse chondrogenic cells. The ED50 for this effect is <50 ng/mL in the presence of 2 ng/mL of recombinant human BMP9 (Cat.GDF-HM002).

  • ALK-1/Activin RL1, His, Human
    • ALK-1/Activin RL1, His, Human

    Immobilized Human GDF-2, No Tag at 2 μg/ml (100 μI/well) on the plate. Dose response curve for ALK-1/Activin RL1, His, Human, His Tag with the EC50 of 6.6ng/ml determined by ELISA.

  • ALK-1/Activin RL1, His, Human
    • ALK-1/Activin RL1, His, Human

    The purity of ALK-1/Activin RL1, His, Human is greater than 95% as determined by SEC-HPLC.

  • ALK-1/Activin RL1, His, Human
    • ALK-1/Activin RL1, His, Human

    ALK-1/Activin RL1, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Activin receptor-like kinase 1 (ALK1)-mediated endothelial cell signalling in response to bone morphogenetic protein 9 (BMP9) and BMP10 is of significant importance in cardiovascular disease and cancer. Structural analyses reveal a tripartite recognition mechanism that defines BMP9 and BMP10 specificity for ALK1, and predict that crossveinless 2 is not an inhibitor of BMP9, which is confirmed by experimental evidence.
Synonyms ACVRLK1; ORW2; ALK1; ALK-1; EC 2.7.11; HHT; HHT2; SKR3; TSR-I; ACVRL1; Activin RLI

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.